Zoetis's Q2 2026 was driven by deteriorating US macro conditions (wellness visits down 7%) and intensified competition in the derm and paras markets. Management pre-announced a guidance cut, shifting to aggressive 'growth-to-net' pricing promotions to protect share, while expressing confidence in long-term fundamentals. US companion animal market is under significant pressure: therapeutic and wellness visits down roughly 7%, with alternative channel growth decelerating.
Zoetis's Q2 2026 was driven by deteriorating US macro conditions (wellness visits down 7%) and intensified competition in the derm and paras markets. Management pre-announced a guidance cut, shifting to aggressive 'growth-to-net' pricing promotions to protect share, while expressing confidence in long-term fundamentals. US companion animal market is under significant pressure: therapeutic and wellness visits down roughly 7%, with alternative channel growth decelerating.
Zoetis's Q2 2026 was driven by deteriorating US macro conditions (wellness visits down 7%) and intensified competition in the derm and paras markets. Management pre-announced a guidance cut, shifting to aggressive 'growth-to-net' pricing promotions to protect share, while…
Guidance · revenue to $8.95B
Management noted softer end market demand persists, with U.S. therapeutic and wellness visits down about 7% overall, and across major categories including OA pain and dermatology, with declines north of 2%. They expect the macro environment and competitive pressures to persist…
New FY2026 guidance incorporates persistent or accelerating competitive/macro pressure, with price realization now expected between 0% and -2% for the year.
Management noted softer end market demand persists, with U.S. therapeutic and wellness visits down about 7% overall, and across major categories including OA pain and dermatology, with declines north of 2%. They expect the macro environment and competitive pressures to persist or accelerate, shaping a cautious outlook for the remainder of the year.
Management repeatedly emphasized persistent macro headwinds, competitive pressures, and the need for aggressive promotions to defend share, while expressing confidence in long-term fundamentals.
“I think if you look at Cytopoint, that's pretty much macro. We don't really have a competitor that's got a full supply against that product. I think let's be clear, if you think about Derm, It is mostly a competitive situation that is driv…”
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| Revenue | FY2026 | $8.9B–$9B | $8.95B | LOWERED |